(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.00% $ 9.26
Live Chart Being Loaded With Signals
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial...
Stats | |
---|---|
Volumen de hoy | 31.00 |
Volumen promedio | 42.00 |
Capitalización de mercado | 3.37B |
EPS | $24.13 ( 2023-11-06 ) |
Last Dividend | $0.121 ( 2023-03-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | 19.29 |
ATR14 | $0 (0.00%) |
Santen Pharmaceutical Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Santen Pharmaceutical Finanzas
Annual | 2023 |
Ingresos: | $279.04B |
Beneficio Bruto: | $166.09B (59.52 %) |
EPS: | $-38.58 |
FY | 2023 |
Ingresos: | $279.04B |
Beneficio Bruto: | $166.09B (59.52 %) |
EPS: | $-38.58 |
FY | 2022 |
Ingresos: | $266.26B |
Beneficio Bruto: | $156.59B (58.81 %) |
EPS: | $68.07 |
FY | 2021 |
Ingresos: | $249.61B |
Beneficio Bruto: | $151.38B (60.65 %) |
EPS: | $17.09 |
Financial Reports:
No articles found.
Santen Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.111 (N/A) |
$0 (N/A) |
$0.121 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0980 | 2014-03-27 |
Last Dividend | $0.121 | 2023-03-30 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $2.40 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.08 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.85 | |
Div. Directional Score | 7.99 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
WTKWY | Ex Dividend Knight | 2023-08-29 | Annually | 0 | 0.00% | |
MHGU | Ex Dividend Junior | 2023-09-14 | Semi-Annually | 0 | 0.00% | |
CNLHO | Ex Dividend Knight | 2023-07-07 | Quarterly | 0 | 0.00% | |
SPXCY | Ex Dividend Knight | 2023-05-05 | Quarterly | 0 | 0.00% | |
HGKGY | Ex Dividend Knight | 2023-08-31 | Annually | 0 | 0.00% | |
APNHY | Ex Dividend Junior | 2023-09-21 | Sporadic | 0 | 0.00% | |
NUBC | Ex Dividend Knight | 2023-09-07 | Quarterly | 0 | 0.00% | |
CZNL | Ex Dividend Knight | 2023-09-18 | Quarterly | 0 | 0.00% | |
TISCF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
IKTSY | Ex Dividend Knight | 2023-09-14 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0918 | 1.500 | 8.16 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0648 | 1.200 | 7.84 | 9.41 | [0 - 0.3] |
returnOnEquityTTM | 0.0924 | 1.500 | -0.0848 | -0.127 | [0.1 - 1] |
payoutRatioTTM | 0.429 | -1.000 | 5.71 | -5.71 | [0 - 1] |
currentRatioTTM | 2.46 | 0.800 | 2.72 | 2.17 | [1 - 3] |
quickRatioTTM | 1.841 | 0.800 | 3.88 | 3.10 | [0.8 - 2.5] |
cashRatioTTM | 0.897 | 1.500 | 6.13 | 9.19 | [0.2 - 2] |
debtRatioTTM | 0.0786 | -1.500 | 8.69 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 20.13 | 1.000 | 3.66 | 3.66 | [3 - 30] |
operatingCashFlowPerShareTTM | 192.60 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 162.21 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.113 | -1.500 | 9.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.606 | 1.000 | 3.24 | 3.24 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.143 | 1.000 | 9.14 | 9.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.03 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.706 | 0.800 | 8.63 | 6.90 | [0.5 - 2] |
Total Score | 11.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 18.69 | 1.000 | 8.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0924 | 2.50 | -0.0545 | -0.127 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 162.21 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.0150 | 1.500 | 9.63 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 192.60 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.429 | 1.500 | 5.71 | -5.71 | [0 - 1] |
pegRatioTTM | -0.000754 | 1.500 | -3.34 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.225 | 1.000 | 6.86 | 0 | [0.1 - 0.5] |
Total Score | 4.85 |
Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico